Last reviewed · How we verify
NCT07025122: MITOFATIGUE
Fatigue in Multiple Sclerosis and Its Relationship to Inflammatory and Neurodegenerative Markers of the Disease
trial in Fatigue in Multiple Sclerosis in 100 participants. Enrolling by invitation.
31 December 2027
Quick facts
| Lead sponsor | University Hospital, Martin |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 26 January 2024 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2028 |
| Sites | 1 location across Slovakia |
Conditions studied
- Fatigue in Multiple Sclerosis — all drugs for Fatigue in Multiple Sclerosis →
- Multiple Sclerosis — all drugs for Multiple Sclerosis →
- Neurofilaments Light Chains — all drugs for Neurofilaments Light Chains →
- GFAP — all drugs for GFAP →
Sponsor
University Hospital, Martin
Who can join
18 and older, any sex, with Fatigue in Multiple Sclerosis or Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is focused on several independent quantifiable biomarkers (sNfL, sGFAP, mitochondrial activity, genetics and fatigue tests) to obtain more detailed information about MS and its progression. Based on the results, investigator will further attempt to predict the course of the disease and manage the therapy more effectively to prevent worsening of the patient's condition.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07025122
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Martin trials
Trials by the same sponsor.
- NCT07274462 — DARA-MVI Study (Daratumumab for Microvascular Inflammation in Kidney Transplantation) · Phase 4 · active not recruiting
- NCT07338929 — Physical Performance Assessment in Kidney Transplant Evaluation · recruiting
- NCT06929637 — Amino Acid Infusion in Kidney Transplant Recipients · NA · not yet recruiting
- NCT07081126 — Daratumumab for Late Antibody-Mediated Rejection · NA · recruiting
- NCT07055984 — Predicting Outcomes in Posttransplant Diabetes Mellitus Via microRNA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07025122 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Martin
- Last refreshed: 17 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07025122.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing